GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GB Sciences Inc (OTCPK:GBLX) » Definitions » Cyclically Adjusted Price-to-FCF

GB Sciences (GB Sciences) Cyclically Adjusted Price-to-FCF : (As of Jun. 06, 2024)


View and export this data going back to 2003. Start your Free Trial

What is GB Sciences Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


GB Sciences Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for GB Sciences's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GB Sciences Cyclically Adjusted Price-to-FCF Chart

GB Sciences Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

GB Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of GB Sciences's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, GB Sciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GB Sciences's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GB Sciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where GB Sciences's Cyclically Adjusted Price-to-FCF falls into.



GB Sciences Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

GB Sciences's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, GB Sciences's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.001/129.4194*129.4194
=-0.001

Current CPI (Dec. 2023) = 129.4194.

GB Sciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.272 99.695 -0.353
201406 -0.271 100.560 -0.349
201409 -0.044 100.428 -0.057
201412 -0.044 99.070 -0.057
201503 -0.014 99.621 -0.018
201506 -0.031 100.684 -0.040
201509 -0.023 100.392 -0.030
201512 -0.031 99.792 -0.040
201603 -0.015 100.470 -0.019
201606 -0.037 101.688 -0.047
201609 -0.010 101.861 -0.013
201612 -0.024 101.863 -0.030
201703 -0.025 102.862 -0.031
201706 -0.018 103.349 -0.023
201709 -0.027 104.136 -0.034
201712 -0.027 104.011 -0.034
201803 -0.043 105.290 -0.053
201806 -0.034 106.317 -0.041
201809 -0.005 106.507 -0.006
201812 -0.009 105.998 -0.011
201903 -0.012 107.251 -0.014
201906 -0.012 108.070 -0.014
201909 -0.003 108.329 -0.004
201912 -0.002 108.420 -0.002
202003 -0.002 108.902 -0.002
202006 -0.001 108.767 -0.001
202009 0.000 109.815 0.000
202012 -0.004 109.897 -0.005
202103 -0.003 111.754 -0.003
202106 -0.002 114.631 -0.002
202109 -0.001 115.734 -0.001
202112 -0.001 117.630 -0.001
202203 -0.002 121.301 -0.002
202206 -0.001 125.017 -0.001
202209 -0.002 125.227 -0.002
202212 -0.001 125.222 -0.001
202303 -0.001 127.348 -0.001
202306 0.000 128.729 0.000
202309 -0.001 129.860 -0.001
202312 -0.001 129.419 -0.001

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GB Sciences  (OTCPK:GBLX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


GB Sciences Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of GB Sciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


GB Sciences (GB Sciences) Business Description

Industry
Traded in Other Exchanges
Address
9205 W. Russell Road, Suite 240, Las vegas, NV, USA, 89148
GB Sciences Inc is active in the healthcare sector. The company is engaged in developing and utilizing technologies in plant biology, cultivation, and extraction techniques combined with biotechnology, and plans to produce medical-grade cannabis, cannabis concentrates, and cannabinoid therapies. It seeks to be a technology and solution company that converts the cannabis plant into medicines, therapies, and treatments for a range of ailments.
Executives
John C Poss director, officer: Chief Executive Officer
Craig Ellins director, 10 percent owner, officer: CEO 3035 EAST PATRICK LANE, SUITE 9, LAS VEGAS NV 89120
Lazarus Management Co Llc 10 percent owner 260 N. JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Lazarus Israel Opportunities Fund Lllp 10 percent owner C/O IBEX GP LLC, 260 NORTH JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Lazarus Investment Partners Lllp 10 percent owner C/O IBEX INVESTORS LLC, 260 NORTH JOSEPHINE STREET, SUITE 300, DENVER CO 80206
Justin B Borus 10 percent owner 260 N. JOSEPHINE STREET, SUITE 300, DENVER CO 80206

GB Sciences (GB Sciences) Headlines

From GuruFocus